Human Molecular Genetics Advance Access published online on May 5, 2004
Human Molecular Genetics, doi:10.1093/hmg/ddh149
© 2004 by Oxford University Press
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Channing Laboratory, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115; Pulmonary Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115
* To whom correspondence should be addressed. E-mail: scott.weiss{at}channing.harvard.edu.
Corticosteroids mediate a variety of immunological actions and are commonly utilized in the treatment of a wide range of diseases. Unfortunately, therapy with this class of medications is associated with a large proportion of non-responders and significant side effects. Inhaled corticosteroids are the most commonly used asthma controller therapy. However, asthmatic response to corticosteroids also varies widely between individuals. We investigated the genetic contribution to the variation in response to inhaled corticosteroid therapy in asthma. The association of longitudinal change in lung function and single nucleotide polymorphisms from candidate genes crucial to the biologic actions of corticosteroids were evaluated in three independent asthmatic clinical trial populations utilizing inhaled corticosteroids as the primary therapy in at least one treatment arm. Variation in one gene, corticotropin releasing hormone receptor 1 (CRHR1) was consistently associated with enhanced response to therapy in each of our three populations. Individuals homozygous for the variants of interest manifested a doubling to quadrupling of the lung function response to corticosteroids compared to lack of the variants (p-values ranging from 0.006 to 0.025 for our three asthmatic populations). As the primary receptor mediating the release of adrenocorticotropic hormone (ACTH), which regulates endogenous cortisol levels, CRHR1 plays a pivotal, pleiotropic role in steroid biology. These data indicate that genetic variants in CRHR1 have pharmacogenetic effects influencing asthmatic response to corticosteroids, provide a rationale for predicting therapeutic response in asthma and other corticosteroid-treated diseases, and suggests this gene pathway as a potential novel therapeutic target.
Article
Corticosteroid Pharmacogenetics: Association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids
2 Channing Laboratory, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115
3 Pulmonary Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115
4 Western Australian Institute for Medical Research, Center for Medical Research, University of Western Australia, Perth 6000, Australia
5 Pulmonary Division, University of Cincinnati, Cincinnati, OH 45867
6 Department of Pediatrics and Medicine, National Jewish Medical and Research Center, Denver, CO 80206
7 Whitehead Institute, Massachusetts Institute of Technology, Cambridge, MA 02141
8 Channing Laboratory, Brigham and Women's Hospital and Harvard Medical School, 181 Longwood Avenue, Boston, MA 02115
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. H. Fanta Asthma N. Engl. J. Med., March 5, 2009; 360(10): 1002 - 1014. [Full Text] [PDF]
|
|
|
|
 |
|
 T. S. Jones, S. C. Kaste, W. Liu, C. Cheng, W. Yang, K. G. Tantisira, C.-H. Pui, and M. V. Relling CRHR1 Polymorphisms Predict Bone Density in Survivors of Acute Lymphoblastic Leukemia J. Clin. Oncol., June 20, 2008; 26(18): 3031 - 3037. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. P. Hall and I. Sayers Pharmacogenetics and asthma: false hope or new dawn? Eur. Respir. J., June 1, 2007; 29(6): 1239 - 1245. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Wechsler, J.-A. O. Shepard, and E. J. Mark Case 15-2007 -- A 20-Year-Old Woman with Asthma and Cardiorespiratory Arrest N. Engl. J. Med., May 17, 2007; 356(20): 2083 - 2091. [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Tebbutt, A. James, and P. D. Pare Single-Nucleotide Polymorphisms and Lung Disease: Clinical Implications Chest, April 1, 2007; 131(4): 1216 - 1223. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. C. Barnes, A. V. Grant, N. N. Hansel, P. Gao, and G. M. Dunston African Americans with Asthma: Genetic Insights Proceedings of the ATS, January 1, 2007; 4(1): 58 - 68. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. P. Hall Pharmacogenetics of Asthma Chest, December 1, 2006; 130(6): 1873 - 1878. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Roden, R. B. Altman, N. L. Benowitz, D. A. Flockhart, K. M. Giacomini, J. A. Johnson, R. M. Krauss, H. L. McLeod, M. J. Ratain, M. V. Relling, et al. Pharmacogenomics: Challenges and Opportunities. Ann Intern Med, November 21, 2006; 145(10): 749 - 757. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D McCarthy, J. L Kennedy, and L. T Middleton Pharmacogenetics in drug development Phil Trans R Soc B, August 29, 2005; 360(1460): 1579 - 1588. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Wechsler and E. Israel How Pharmacogenomics Will Play a Role in the Management of Asthma Am. J. Respir. Crit. Care Med., July 1, 2005; 172(1): 12 - 18. [Full Text] [PDF]
|
|
|
|
|
|
S. T. Weiss, S. L. Lake, E. S. Silverman, E. K. Silverman, B. Richter, J. M. Drazen, and K. G. Tantisira Asthma Steroid Pharmacogenetics: A Study Strategy to Identify Replicated Treatment Responses Proceedings of the ATS, December 1, 2004; 1(4): 364 - 367. [Abstract] [Full Text] [PDF]
|
|